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Safety and efficacy of long-acting somatostatin treatment in
autosomal-dominant polycystic kidney disease.
Background. The fluid filling renal cysts in human polycystic
kidneys is secreted chiefly by the tubular epithelium lining the
cysts via secondary chloride transport. Inhibiting this process
by somatostatin therapy should induce shrinking of renal cysts.
Methods. In this randomized, cross-over, placebo-controlled
trial we compared the risk/benefit profile of 6-month treatment
with long-acting somatostatin (octreotide-LAR, 40 mg intra-
muscularly every 28 days) or placebo in autosomal-dominant
polycystic kidney disease (ADPKD) patients with mild-to-
moderate renal insufficiency and no evidence of other kidney
disease. Volumes of kidney structures were evaluated by a two-
slice computed tomography (CT) scanner; while glomerular fil-
tration rate (GFR) was estimated by iohexol plasma clearance.
Results. One patient on somatostatin and one on placebo
were prematurely withdrawn because of nonsymptomatic, re-
versible colelithiasis and asthenia, respectively. In the remain-
ing 12 patients somatostatin was well tolerated. Kidney volume
increased by 71 ± 107 mL (P < 0.05) on somatostatin and by
162 ± 114 mL (P < 0.01) on placebo. The percent increase
was significantly lower on somatostatin (2.2 ± 3.7% vs. 5.9 ±
5.4%) (P < 0.05). Cystic volume tended to increase less on
somatostatin than on placebo (3.0 ± 6.5% vs. 5.6 ± 5.8%).
The “parenchymal” volume nonsignificantly increased by 2.5 ±
8.4% on placebo and slightly decreased by 4.4 ± 8.9% on so-
matostatin. The GFR did not change significantly during both
treatment periods.
Conclusion. In ADPKD patients, 6-month somatostatin ther-
apy is safe and may slow renal volume expansion. This may re-
flect an inhibited growth in particular of smallest cysts beyond
the detection threshold of CT scan evaluation. Whether this ef-
fect may prove renoprotective in the long term should be tested
in additional trials of longer duration.
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Autosomal-dominant polycystic kidney disease
(ADPKD) is the most common hereditary renal
disease, responsible for 8% to 10% of end-stage renal
disease (ESRD) in Western countries [1]. ADPKD
shows genetic heterogeneity, with at least three different
genes implicated: the PKD1 gene (85% of the cases),
the PKD2 gene (15% of the cases), and probably a
PKD3 gene not yet identified. PKD1 is a more severe
condition with an average age of ESRD at about 54
years compared to 73 years for PKD2 [1]. Moreover,
patients with ADPKD have a faster decline in glomeru-
lar filtration rate (GFR) than patients with other renal
diseases, at comparable levels of blood pressure control
and proteinuria, and do not seem to benefit to the same
extent from angiotensin-converting enzyme (ACE)
inhibitor therapy [2–4]. A reasonable explanation for
these findings is that progression in ADPKD is largely
related to the development and growth of cysts and
concomitant disruption of normal renal tissue [5]. Thus,
renal protective interventions in ADPKD, in addition
to achieving maximal reduction of arterial blood pres-
sure and proteinuria, and limiting the effects of other
potential promoters of disease progression such as
dyslipidemia, chronic hyperglycemia, or smoking, should
also be specifically aimed to correct the dysregulation of
epithelial cell growth, secretion, and matrix deposition
that is characteristic of the disease [5]. Current thera-
pies are inefficient in arresting or even in slowing the
rate of progressive loss of renal function. As a result,
approximately 50% of these patients will need renal
replacement therapy by 60 years of age [6].
The fluid filling renal cysts in human polycystic kid-
neys, as well as in many forms of experimental cystic dis-
ease in rats, is formed chiefly by a process of secretion
by the tubular epithelium lining the cysts [7, 8]. Secretion
and reabsorption take place at approximately the same
rate, with secretion slightly higher, so that the amount
of fluid in the cysts increases slowly over time. This pro-
cess of active secretion, via the molecular mechanism of
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secondary active chloride transport [9], is also responsi-
ble for secretion of fluid into the lumen by proximal renal
tubules in teleost and elasmobranch fishes [10, 11] and in
the rectal (salt-excreting) gland of elasmobranchs [12].
In the shark, rectal gland chloride secretion is markedly
inhibited by somatostatin in a way suggesting inhibition
of adenylcyclase and of post-cyclic adenosine monophos-
phate (cAMP) events as well as an inhibition of secre-
tion stimulated by agents that do not generate cAMP [13,
14]. Evidence that specific receptors for somatostatin are
present in human kidneys [15] suggests the possibility that
somatostatin treatment of patients with ADPKD might
inhibit fluid formation and eventually induce shrinking
of renal cysts.
Somatostatin is a cyclic 14 aminoacid peptide secreted
by pancreatic islets (D cells), gastrointestinal tract, ner-
vous system, and thyroid gland [16]. There are two native
biologically active forms of somatostatin, and a number
of synthetic analogues have been described [17]. Genes
for five somatostatin receptor subtypes have been cloned
and are named sst1 to sst5. All receptors bind molecular
forms of somatostatin as well as somatostatin analogues
with varying affinity for the agonists. The sst2 receptor is
present in kidney tissue, and shows a high affinity for the
somatostatin analogue octreotide [15]. Effector systems
of sst2 receptors are inhibitors of adenylate cyclase and
stimulators of phosphatase and phospholipase C [16]. Re-
cently somatostatin analogues have become available and
have been used with negligible side effects for long-term
treatment (up to 8 to 12 months) of multiple endocrine
tumors [18].
We suspected a potentially beneficial effect of somato-
statin in patients with ADPKD from observing a female
patient on continued treatment with the somatostatin
analogue octreotide for about 2 years to prevent un-
controlled growth hormone secretion from an adenoma
of the pituitary gland. A comparative analysis of two
computed tomography (CT) scans taken at the time oc-
treotide treatment was started and 2 years later failed to
detect any appreciable change in cyst areas (Fig. 1). This
finding, combined with a stable serum creatinine concen-
tration, suggested possible inhibition of the growth of re-
nal cysts that might have prevented further damage to
the residual functioning kidney parenchyma. We there-
fore designed a pilot study to assess the safety-profile and
the structural and functional effects of a long-acting so-
matostatin in patients with ADPKD and varying degrees
of renal insufficiency. The results of this clinical study
form the basis of the present report.
METHODS
This randomized, longitudinal, cross-over study com-
pared the safety and efficacy of treatment for 6 months
with long-acting somatostatin or placebo in adult patients
Fig. 1. Representative images of abdominal computed tomography
(CT) scans of a patient with autosomal-dominant polycystic kidney
disease (ADPKD), before (A) and after 2-year treatment (B) with the
somatostatin analogue octreotide for an adenoma of the pituitary gland.
with ADPKD. The safety and tolerability of somatostatin
treatment was assessed by comparing the incidence of
serious and nonserious adverse events as well as of clin-
ically relevant changes in several laboratory parameters
throughout both treatment periods. The efficacy profile
was assessed by comparing the effects of the two study
treatments on kidney structure and functional determina-
tions. The main efficacy variable was total kidney volume.
Secondary efficacy variables were cystic and parenchyma
volumes, determined by spiral CT scan evaluations, and
GFR, as determined by iohexol plasma clearance [19],
recorded at baseline and at the end of each treatment
period. The morpho-functional relations between con-
comitant changes in kidney volumes and GFR during
treatment period and during placebo were also evaluated.
The study protocol was approved by the Ethical Commit-
tees of the Clinical Research Center for Rare Diseases of
the Mario Negri Institute and of the Azienda Ospedaliera
Ospedali Riuniti di Bergamo. Before inclusion, eligible
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patients provided their written informed consent accord-
ing to the Declaration of Helsinki guidelines.
Patient selection
Patients aged 18 years or older, with a clinical and echo-
graphic diagnosis of ADPKD and a serum creatinine con-
centration <3.0 mg/dL, but >1.2 mg/dL (males) or >1.0
mg/dL (females) were selected for study participation.
Patients with concomitant systemic, renal parenchymal
or urinary tract disease, diabetes, overt proteinuria (uri-
nary protein excretion rate >1 g/24 hours), or abnormal
urinalysis suggestive of concomitant, clinically significant
glomerular disease, urinary tract lithiasis, infection or ob-
struction, biliary tract lithiasis or obstruction, more than
two hemorrhagic or complicated cysts, cancer and ma-
jor systemic diseases that could prevent completion of
the planned follow-up or interfere with data collection
or interpretation, psychiatric disorders, and any condi-
tion that could prevent full comprehension of the pur-
poses and risks of the study were not considered eligible
for study participation. Pregnant or lactating women or
fertile women without effective contraception were also
excluded from the study.
Study design
At a screening visit, potentially eligible patients had
an ultrasound evaluation of the kidneys and liver. Those
with no evidence of urinary tract or gallbladder lithia-
sis and satisfying all the other inclusion/exclusion criteria
entered the study. After 5 minutes rest in sitting position,
they had three blood pressure measurements (Korotkoff
phase I and V) taken by a standard sphygmomanometer
2 minutes apart at the dominant arm, and the mean of the
three readings was recorded for statistical analyses. Blood
and urine samples were taken in the morning with the
patient fasting from the evening before, for routine lab-
oratory evaluations, including routine hematochemistry,
renal and liver function tests, and coagulation tests. The
GFR was measured by the iohexol plasma clearance tech-
nique, as described in details previously [19]. Parenchy-
mal resistive indexes of both kidneys were evaluated by
Doppler ultrasounds. Total kidney, cysts, and parenchy-
mal volume were evaluated by spiral CT and morphome-
tric analysis as described below.
After baseline evaluations, patients were randomly al-
located to start a 6-month treatment period with the
long-acting somatostatin octreotide-LAR (Sandostatin-
LAR Depot; Novartis Pharma AG, Basel, Switzerland)
or with placebo (40 mg intramuscularly for 28 days, given
as two intragluteal 20 mg injections). Every 2 months
blood pressure and routine laboratory tests, including
blood glucose, serum creatinine, creatinine clearance,
complete blood cell count, and 24-hour urinary protein
excretion rate, were evaluated and a kidney and liver ul-
trasound evaluation was repeated. At 6 months, all the
measurements performed at baseline evaluation (includ-
ing CT and GFR evaluations) were repeated. Then, each
patient crossed over to the other treatment arm. The same
measurements performed during the first treatment pe-
riod were repeated every 2 months and at completion
of the second treatment period, all baseline evaluations
were repeated before patients were discharged from the
study.
No specific change in diet and pharmacologic treat-
ment was introduced throughout the study period,
unless deemed clinically appropriate to control blood
pressure or limit the signs of renal or liver dysfunction. In
particular only adjustments in the doses of the ongoing
antihypertensive treatments were recommended in or-
der to maintain the same level of blood pressure control
(target systolic/diastolic blood pressure <130/80 mm Hg)
throughout the whole study period. Concomitant changes
in blood glucose levels and need for antidiabetic therapy
throughout the study period were carefully monitored
since they could be taken as indirect evidence of an unto-
ward effect of somatostatin therapy on insulin sensitivity
and glucose metabolism.
Spiral CT scanning and volumetric analyses
Volumes of kidney structures were evaluated by a two-
slice CT scanner (CT-Twin) (Elscint, Haifa, Israel). A
single breath-hold CT scan was used to eliminate arti-
facts due to respiratory motion. CT acquisitions were
started 90 seconds after start of an intravenous injec-
tion of 170 mL of nonionic contrast agent (Iopamiro)
(Bracco, Milano, Italy) at a rate of 2.5 mL/second. Main
scanning parameters were maintained constant for all
acquisitions (voltage 120 kV, current 230 mA, field-of
view 43 cm, matrix 512 × 512, collimation 5 mm, pitch
1, increment 3 mm, and overlap >50%). Digital CT im-
ages were transferred to a PC workstation in Dicom for-
mat and used for digital morphometry, using in-house
developed software (C++ and Insight Toolkit, ITK)
[www.itk.org] [20]. Briefly, kidneys were initially out-
lined by a trained radiologist (G.F.) with manual oper-
ation on digital images. The operator was not required
to identify precisely the kidney boundary where a fat re-
gion surrounded the organ, but to place the outline at
the organ interface when other tissues, such as the liver,
were in contact with the kidney. The total volume of the
right and left kidney, of the parenchyma and of the cysts
was evaluated by automatic segmentation of kidney im-
ages. To obtain this result images were initially enhanced
by anisotropic diffusion filtering [21] whose implemen-
tation is available in the ITK library. After smoothing
image segmentation was performed by a histogram-based
statistical approach known as Otsu’s thresholding [22].
Briefly, in this method the image intensity histogram is
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Fig. 2. Two representative images of kid-
ney segmentation in two different patients
with cyst different morphology of cyst and
parenchymal volumes. Original images (A
and C) are compared with corresponding
pixel identification (B and D). In segmented
images white pixels represent parenchymal
volume, dark gray pixels represent cyst area,
while light gray pixels represent transitional
area between parenchyma and cyst volume.
partitioned in a previously assumed number of classes
(N = 3) as to minimize the between-class variance. In-
tensity of image pixels of the kidney were then assigned
automatically to one of these areas, respectively, the
parenchyma, the cysts, and an intermediate area that
we considered to be a transition from parenchyma to
cyst area likely deriving from the partial volume effect.
A representative example of this image segmentation
is reported in Figure 2. The number of pixels of the
parenchyma and cysts areas was used to calculate total
volume of these structures in left and right kidney, tak-
ing into account pixel dimensions as contained in Dicom
images and the distance between two slices. Thus, two
volumes were identified, a cystic volume and parenchy-
mal volume. The cystic volume included cysts of approxi-
mately 3 mm in diameter or larger, the parenchymal vol-
ume included apparently normal parenchyma as well as
parenchyma with early changes consisting of initial tubu-
lar dilatation and small cysts below the detection thresh-
old of the CT scans. To account for this approximation,
this volume was identified by the term parenchymal vol-
ume inserted between inverted commas. The residual kid-
ney tissue, accounting for about 20% of the total kidney
volume, could not be unequivocally assigned to either
cystic or parenchyma volume and was not considered in
the analyses. A three-dimensional representation of these
kidney volumes is reported in Figure 3. The results of im-
age segmentation were verified by an expert radiologist.
Finally, the accuracy of volume measurements was eval-
uated as previously described by King et al [5] using a
phantom. This validation permitted to estimate a mean
error between calculated and actual volumes of the phan-
tom to be less than 0.7%.
Statistical analysis
This was an exploratory study aiming to have at least
ten patients available for full-set analyses, a figure con-
sidered a priori to provide a reasonable sample size for a
preliminary evaluation of the efficacy and safety profile of
the study drug. Two factors—the availability of a sensitive
and reproducible technique such as spiral CT allowing for
precise volumetric evaluations, and the cross-sectional
design preventing the confounding effect of between-
patients variability—were expected to permit powerful
analyses with a relatively small sample size. Data are
given as mean ± standard deviation (SD) or median and
range as specified.
RESULTS
Baseline characteristics
Fourteen patients entered the study. A positive family
history for ADPKD was obtained for each subject. On
the basis of the history, nine patients had the PKD1 form
and one the PKD2 form (as suggested also by the linkage
analysis). In the remaining four subjects the differential
diagnosis between PKD1 and PKD2 was uncertain. One
patient was withdrawn after 5 months of somatostatin
therapy because of the detection at routine ultrasound
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Fig. 3. Three-dimensional representation of the outer surface of renal cyst (in green) and parenchymal volume (in red). A numeric model of the
abdominal aorta was digitally embedded in the three-dimensional representation. (A) Outer view of cyst volume. (B and C) Contemporary view of
residual parenchymal volume and portions of the cyst volume. (D) Volume occupied by parenchymal tissue.
evaluation of two, nonsymptomatic, small gallstones that
dissolved after 2 months’ treatment with ursodeoxy-
cholate acid. Another patient was withdrawn after 3
months of placebo treatment because of asthenia. Thus,
12 patients (nine males and three females) completed
the study. Their main characteristics at study entry are
summarized in Table 1. Two patients were normotensive.
The remaining ten patients were on renin-angiotensin
system (RAS) inhibition therapy, with ACE inhibitors
(N = 9) or an angiotensin II receptor blocker (N = 1).
In five patients the RAS inhibitor was a component of
a multidrug regimen that included a beta blocker (N =
1), a beta blocker and a calcium channel blocker (N =
1), a diuretic and a calcium channel blocker (N = 2),
or a diuretic and a beta blocker (N = 1). Nine pa-
tients had a serum creatinine equal to or greater than
1.3 mg/dL. In four patients urinary albumin was within
normal limits; seven were microalbuminuric and one was
macrolbuminuric.
Table 1. Demographic, clinical, and kidney structural data at baseline
Age years 44.5 (35-58)
Systolic blood pressure mm Hg 144.1 ± 11.6
Diastolic blood pressure mm Hg 94.2 ± 11.9
Serum creatinine mg/dL 1.9 (1.0-3.4)
Glomerular filtration rate mL/min/1.73 m2 57.1 (24.4-95.3)
Albuminuria lg/min 27 (9-437)
Resistive index, left 0.61 ± 0.07
Resistive index, right 0.63 ± 0.06
Kidney volume mL 2435 ± 966
Cyst volume mL 1631 ± 838
Parenchymal volume mL 242 ± 61
Residual volume mL 562 ± 277
Data are mean ± SD or median and (range).
Mean values of kidney volumes, as determined by CT
investigation and digital image processing are reported
in Table 1. Total (left + right) kidney volumes were quite
heterogeneous within the study group, ranging from 1498
to 4294 mL. Five patients had a total kidney volume
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Table 2. Main clinical and laboratory parameters at start and end of each treatment period with placebo or somatostatin
Placebo Somatostatin
Start End Start End
Systolic blood pressure mm Hg 143 ± 12 143 ± 9 141 ± 8 143 ± 13
Diastolic blood pressure mm Hg 94 ± 12 91 ± 9 91 ± 12 94 ± 14
Creatinine mg/dL 1.8 ± 0.9 2.1 ± 1.0 2.1 ± 1.1 2.2 ± 1.1
Creatinine clearance mL/min/1.73 m2 54.9 ± 21.9 52.4 ± 25.0 56.7 ± 29.1 53.5 ± 28.9
Aspartate aminotransferase (AST) U/L 21.9 ± 6.2 22.5 ± 7.6 23.6 ± 5.6 25.0 ± 5.6
Alanine aminotransferase (ALT) U/L 23.5 ± 7.7 25.0 ± 11.8 30.2 ± 13.4 29.1 ± 13.8
Gamma glutaryl transaminase (GGT) U/L 17.3 ± 13.8 21.0 ± 14.5 19.5 ± 14.6 19.0 ± 15.2
Biliary acid lmol/L 3.3 ± 1.8 3.4 ± 1.3 4.1 ± 1.8 4.2 ± 1.9
Alkaline phosphatase U/L 60.8 ± 17.5 63.0 ± 19.4 62.5 ± 18.2 61.9 ± 18.8
Activated partial thromboplastin time (APTT) ratio 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
Prothrombin time (PT) INR 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.1 1.0 ± 0.1
Calcium mg/dL 9.1 ± 0.3 9.2 ± 0.2 8.6 ± 1.7 8.6 ± 1.7
Phosphorus mg/dL 3.6 ± 0.7 3.7 ± 0.7 3.7 ± 0.8 3.6 ± 0.7
Sodium mEq/L 141.5 ± 2.1 142.1 ± 2.1 141.8 ± 2.5 142.2 ± 1.7
Potassium mEq/L 4.4 ± 0.4 4.3 ± 0.3 4.4 ± 0.4 4.4 ± 0.4
Blood glucose mg/dL 93.9 ± 12.0 93.5 ± 14.0 100.0 ± 16.0 102.8 ± 14.9
Uric acid mg/dL 6.7 ± 1.6 6.9 ± 1.3 7.2 ± 1.8 7.3 ± 1.8
Data are mean ± SD.
larger than 2 L. Most of the kidney volume was occupied
by radiologically detectable cysts averaging 65% (range
52% to 86%). Ten patients had a GFR below the normal
range (80 to 120 mL/min/1.73 m2). There was a marginally
significant correlation between GFR and parenchymal
volume (r = 0.52, P = 0.08). No correlation was found
between GFR and total or cyst volume. The resistive in-
dex of both kidneys was below 0.80 in all patients.
Safety and tolerability
Somatostatin treatment was well tolerated in all pa-
tients who completed the study. Watery diarrhea was re-
ported in three patients and spontaneously recovered in
all within the first month of treatment. As shown in Table
2, blood pressure was relatively well controlled without
significant changes throughout both treatment periods.
No change in antihypertensive therapy was introduced
throughout the study period. No clinically relevant or sta-
tistically significant change in the monitored laboratory
parameters occurred throughout the two treatment peri-
ods (Table 2). In one patient the blood glucose increased
above 125 mg/dL during placebo treatment. This mild
increase did not require antidiabetic therapy and per-
sisted after the study was ended. There was a transient
and marginal increase in alanine aminotransferase lev-
els in two patients on somatostatin and in one patient on
placebo. These abnormalities disappeared spontaneously
within 1 or 2 months.
Kidney volumetric analysis
Total kidney, and cystic volumes before and after treat-
ment with somatostatin or placebo in each individual pa-
tient are shown in Figure 4. On average, the volume of
both kidneys significantly increased by 71 ± 107 mL (P
< 0.05) during somatostatin treatment and by 162 ± 114
mL (P < 0.01) during placebo (Table 3) (Fig. 5). Thus,
on somatostatin the volume increase was about 60% less
than on placebo. Total volume increase during placebo
treatment was mainly due to a significant increase in the
volume occupied by renal cysts (106 ± 105 mL) (P <
0.01) and was only marginally influenced by concomitant
changes in the “parenchymal” volume, which increased
by only 9 ± 22 mL (Table 3) (Fig. 5). The increase in kid-
ney volume during treatment with somatostatin was en-
tirely due to the concomitant increase in the volume iden-
tified as renal cysts (61 ± 106 mL), since the “parenchy-
mal” volume actually numerically decreased by 10 ± 24
mL (Table 3) (Fig. 5).
As reported in Figure 5, on somatostatin treatment the
percent change in total kidney volume was significantly
lower than on placebo (2.2 ± 3.7% vs. 5.9 ± 5.4%, re-
spectively) (P < 0.01). This difference was the result of
a numerically lower growth of cyst volume on somato-
statin than on placebo (3.0 ± 6.5% vs. 5.6 ± 5.8%) and
of opposite changes in “parenchymal volume,” that non-
significantly decreased by 4.4 ± 8.9% on somatostatin,
but actually increased by 2.5 ± 8.4%, on placebo (Fig. 5).
There were no significant correlations between changes
in total kidney, parenchymal or cyst volumes, and con-
comitant changes in GFR or serum creatinine, or resistive
index throughout both treatment periods.
Renal functional analysis
As reported in Table 3, GFR did not change signifi-
cantly on placebo or on somatostatin. Serum creatinine
numerically increased both during placebo and treatment
period, but these changes did not reach statistical sig-
nificance. Albumin excretion rate did not change either
during placebo or during treatment period. The resistive
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Fig. 4. Total kidney and cysts volumes in
each individual patient before and after so-
matostatin or placebo treatment. Symbols
represent individual patients.
Table 3. Kidney functional and structural parameters before and after 6-month treatment with placebo or somatostatin
Placebo Somatostatin
Before After Before After
Serum creatinine mg/dL 2.0 ± 1.0 2.2 ± 1.1 1.9 ± 0.8 2.1 ± 1.1
Diuresis mL/24 hours 1954 ± 599 2054 ± 590 1979 ± 530 2046 ± 667
Glomerular filtration rate mL/min/1.73 m2 57.9 ± 22.4 57.7 ± 25.7 59.5 ± 25.2 54.0 ± 23.6
Urinary albumin excretion lg/min 33 (9-543) 49 (8-595) 31 (13-437) 42 (7-543)
Resistive index, left 0.61 ± 0.07 0.64 ± 0.08 0.61 ± 0.08 0.64 ± 0.05
Resistive index, right 0.64 ± 0.06 0.65 ± 0.06 0.63 ± 0.07 0.66 ± 0.07
Total kidney volume mL 2461 ± 959 2623 ± 1021a 2551 ± 1053 2622 ± 1111b
Cyst volume mL 1656 ± 826 1762 ± 882 1709 ± 908 1770 ± 941
Parenchymal volume mL 242 ± 62 251 ± 72 247 ± 67 237 ± 65
Residual volume mL 562 ± 280 609 ± 325 595 ± 323 615 ± 347
Data are mean ± SD or median and (range). Student t test for paired data.
aP < 0.05; bP < 0.01 vs. start.
index did not change significantly throughout either treat-
ment periods (Table 2).
DISCUSSION
The hypotheses driving the present study were (1) that
the growth of renal cysts in polycystic kidneys over time
represents a slight cumulative excess of secretion over
reabsorption and (2) that the process of secretion (via
secondary active transport of chloride) might be inhibited
by somatostatin, as it is in the rectal gland of the shark
[13, 14].
We found that in adult patients with ADPKD and
different degrees of renal insufficiency, treatment for 6
months with the somatostatin analogue octreotide was
safe and well tolerated. Moreover, octreotide, as com-
pared to placebo, retarded the time-dependent increase
in total kidney volume to a significant extent. The net
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Fig. 5. Average changes in kidney volume,
cyst volume, and “parenchymal” volume, and
in the whole study group at the end of placebo
and somatostatin treatment. Student t test for
paired data.
effect on kidney volume resulted from an action of the
drug on cyst volume and on parenchyma volume. While
the volume of radiologically detectable cysts was not
appreciably reduced by somatostatin treatment, aver-
age “parenchymal” volume was reduced while on ac-
tive treatment, but increased on placebo. The GFR was
marginally correlated with “parenchymal volume,” but
not with total or cyst volumes, and tended to decrease on
octreotide.
Of note, despite the different procedures used for the
evaluation of kidney volumes and function [spiral CT
scanning and iohexol plasma clearance versus magnetic
resonance imaging (MRI) and iothalamate renal clear-
ance, respectively] the morphologic and functional data
in our present series were very well comparable with
those in the remarkably larger series of patients with sim-
ilar clinical characteristics included in the Consortium for
Radiologic Imaging Studies of Polycystic kidney disease
(CRISP) [23].
Safety
Only one patient had to interrupt somatostatin ther-
apy prematurely because of asymptomatic cholelithiasis
that disappeared after a few months of treatment with
ursodeoxycholate acid. Octreotide has occasionally been
reported to favor the development of gallstones, that,
however, promptly dissolved by ursodeoxycholic acid
[24]. Three patients reported a watery diarrhea that spon-
taneously recovered during the first month of somato-
statin therapy; this has also been occasionally reported
as a side effect of octreotide treatment. No deleterious
changes in laboratory parameters were observed during
somatostatin therapy. In particular, in the study group as
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a whole there were no significant changes in blood glu-
cose and hemoglobin A1c (HbA1c) levels. In one patient
on placebo, however, there was an increase in blood glu-
cose above 125 mg/dL that did not require pharmacologic
treatment. These reassuring findings are consistent with
previous evidence that chronic treatment with somato-
statin occasionally increased fasting blood glucose and
HbA1c, or reduced glucose tolerance, but never caused
new onset diabetes [25]. Finally, we observed a marginal
and transient increase in alanine aminotransferase levels,
without any other change in liver function parameters,
in two patients on somatostatin and in one on placebo.
These abnormalities recovered spontaneously and may
have been related to concomitant cystic disease of the
liver.
Efficacy
The heterogeneous effects on cystic and “parenchy-
mal” volumes most likely reflected different effects of
somatostatin therapy in modulating the development and
growth of cysts at different stages of the disease. In
early stages of ADPKD, cysts are generated from tubule
segments that are perfused by glomerular filtrate [26].
These cysts have a diameter of a few millimeters, below
the detection threshold of the present CT scan evaluation.
Thus, the “normal” parenchyma identified by CT scan
evaluation probably included not only normal nephrons
but also nephrons with early cystic changes that precede
the development of radiologically detectable cysts. As
the cysts enlarge beyond a few millimeters in diameter,
they are detected by CT scan. At this stage, about 75%
of the cysts irreversibly lose their connections with the
original tubule and become isolated sacs [1]. As a con-
sequence, the normal architecture and function of the
original tubules are irreversibly lost, with a consequent
reduction in functioning nephron mass. At the same time,
isolated cysts continue to grow in a process that may accel-
erate kidney damage through compression and ischemia
of contiguous renal parenchyma [26, 27].
In evaluating the results of this short-term trial of so-
matostatin, the following facts should be kept in mind.
First, somatostatin has been reported to depress GFR
slightly and reversibly in human subjects [28–32]. Any
tendency for improvement in GFR during treatment with
somatostatin might be counteracted by this reversible
functional effect. Second, the portion of polycystic kid-
neys identified radiologically as “parenchyma” probably
contained many microscopic cysts, as deduced from the
histologic examination of such kidneys at postmortem
[33]. Third, the ratio of cyst surface to volume is much
larger for small cysts than for bigger ones, so that the
rates of secretion and reabsorption by the cyst epithe-
lium may be expected to be proportionately greater per
unit of cyst volume. It might be predicted, therefore, that
inhibition of secretion by cysts would have its first de-
tectable effect on the volume of small cysts. Perhaps this
is responsible for the diminution in the “parenchymal”
segment of kidney volume in patients treated with oc-
treotide as compared with placebo treatment. It is also
possible that the reduction in parenchyma volume ob-
served during somatostatin therapy reflects inhibition of
the tubular cell proliferation that precedes cyst develop-
ment and detachment from the tubuli of origin [34].
This interpretation is consistent with a possible effect
of somatostatin on cAMP signaling that goes beyond an
effect on fluid secretion. Indeed, evidence based on stud-
ies of cyst epithelial cells in vitro points strongly to a role
for cAMP in determining the rate of cyst epithelial cell
growth and fluid secretion [35], two biologic processes
that are of fundamental importance in the expansion of
renal cysts. Recent findings that in experimental mod-
els of human autosomal-recessive [36] or dominant [37]
PKD these biological processes are effectively inhibited
by agents that antagonize cAMP production and activity
can be taken to suggest that somatostatin treatment may
prevent cyst development and growth by directly affect-
ing cell proliferation and apoptosis. Indeed, somatostatin
is known to inhibit cAMP generation in Madin-Darby
canine kidney (MDCK) cells [38] and in microdissected
rat medullary and cortical collecting ducts [39] and to
antagonize the effects of vasopressin in the toad urinary
bladder [40] and dog collecting dugs [41] in a manner con-
sistent with inhibition of basal and hormone-stimulated
adenyl cyclase. Data that cAMP and agonists of adenyl cy-
clase stimulate the proliferation of epithelial cells derived
from ADPKD kidneys provide convincing evidence that
cAMP may have a cystogenetic role also in human dis-
ease [35] and can be taken to suggest that in our present
study the effects of somatostatin therapy were at least
in part mediated by the inhibition of cAMP-dependent
polycystic kidney cell proliferation [42]. If early enough,
these effects, in addition to preventing cyst formation
and growth, might preserve the original tubular archi-
tecture, which in turn might prevent further loss of tissue
and deterioration of renal function over time. The inhi-
bition of compensatory hypertrophy and hyperplasia of
residual glomerular/tubular units still not involved in cyst
development and growth might also contribute to the
reduction in “parenchyma” volume observed during
somatostatin therapy and help to explain the slight
GFR reduction observed during somatostatin therapy.
Octreotide is known to decrease the GFR in healthy
individuals [29, 30], as well as in patients with type 1
diabetes [29–31] or liver cirrhosis [32], perhaps by in-
hibiting the secretion of growth hormone. Such an effect
might counteract the tendency to compensatory hyperfil-
tration that accompanies the glomerular and tubular hy-
pertrophy/hyperplasia of residual functioning nephrons.
In the long-term, glomerular hyperfiltration may cause
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premature glomerular obsolescence with worsening
proteinuria, declining filtration power, and eventual
glomerulosclerosis. Total GFR is maintained until pro-
gressive parenchymal loss precludes complete compen-
sation. At that point, total GFR begins to fall rapidly
by mechanisms no longer dependent on cyst growth,
resulting in irreversible kidney failure [33]. Thus, long-
term somatostatin therapy might prove renoprotective
in patients with ADPKD not only by preventing cyst
development and inhibiting tubular secretion, but also
by inhibiting the maladaptive events sustained by, and
contributing to, progression to nephron loss.
The good safety profile and the marginal reduction
in renal growth demonstrated in this short-term study
suggest the feasibility of a randomized trial in larger se-
ries of ADPKD patients to verify whether long-term so-
matostatin treatment may eventually provide effective
renoprotection. At the present time no treatment that
may appreciably affect the relentless progression of the
disease to end-stage has been identified. Studies are also
needed to assess the effects of somatostatin therapy in the
liver cystic disease that so often accompanies ADPKD.
CONCLUSION
In patients with ADPKD somatostatin therapy given
for 6 months is safe and may slow renal volume expansion,
largely by preventing the growth of the “parenchymal”
volume. Whether this effect may prove renoprotective
in the long term should be tested in additional trials of
larger duration.
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